Researchers working on the first ever UK-led international surgical breast cancer clinical trial are paying tribute to hundreds of women who are helping them investigate the potential over-treatment of early breast cancer.
October is Breast Cancer Awareness Month and the research team running the POSNOC trial at the Nottingham Clinical Trials Unit, University of Nottingham and Royal Derby Hospital are asking more women to consider helping this unique project.
The £2.9 million NIHR-funded POSNOC trial is looking at the armpit treatment given to women who are diagnosed with early stage breast cancer when the cancer has spread to the lymph nodes under the arm. Currently statistics show that the cancer returns at the same rate in women who are given armpit treatment and in women who have not had armpit treatment.
The trial is trying to establish if armpit treatment is of benefit to women with cancer spread to one or two lymph glands who are receiving chemotherapy or hormone treatment.
At present, normal treatment for early breast cancer patients with lymph node spread is either surgical removal of the armpit lymph nodes or radiotherapy. POSNOC is recruiting 1,900 women in the UK, Australia and New Zealand to be randomised into either armpit treatment or not, to find out whether the extra surgery and/or radiotherapy adds any additional benefit to treating the armpit lymph nodes with drugs. This is important as one in five women who undergo armpit treatment may develop incurable lymphoedema — swelling of the arm — that can seriously affect their quality of life after treatment.
School teacher Fiona McOwan from Dunfermline in Scotland was diagnosed with early stage breast cancer with lymph node spread in 2007. Fiona said: “I had been told about the risk of developing lymphoedema following breast cancer surgery with node removal, and was shown a photograph of a swollen arm by my breast care nurse. In May 2007 I began to experience a feeling in my lower left arm that was between an ache and a bruise. I did not associate this with lymphoedema until I read an article in Vita, the magazine of Breast Cancer Care, on all the possible indicators of the condition. There it was — an aching or bruised feeling in the arm!
“I was subsequently diagnosed with lymphoedema in early June by a specialist physiotherapist in NHS Fife. Since then I have worn my compression sleeve daily and practised Simple Lymph Drainage (SLD) every night. I take good care of my skin, particularly in sun, and am now considered to be under self-management. I think the POSNOC trial is particularly interesting in terms of the decisions that can be made about removal or not of ancillary lymph nodes and the full implications of informed consent.”
Chief Investigator on the POSNOC trial, Associate Professor Amit Goyal, from the Royal Derby Hospital said: “No woman should undergo unnecessary treatment that may cause debilitating side effects like arm swelling. Arm problems after removing the lymph glands or giving radiotherapy are often a persistent reminder when the cancer has long gone. Women want to move on and draw a line once they have finished cancer treatment. Towards this, the POSNOC study will take us a step closer to optimise breast cancer treatment and find out whether we can treat the lymph glands by drugs rather than by removing them or giving radiotherapy.Together, we can #makelymphoedemahistory.
One in five women diagnosed are found to have cancer in lymph nodes under the arm so the trial has wide implications for future treatment protocols. So far more than 850 women have been recruited to help the POSNOC study but a further 1,000 are needed to fulfil the trial’s remit and deliver a robust analysis of the benefit, or not, of lymph node surgery and radiotherapy.
More details on the trial and information on how to take part after a breast cancer diagnosis is available on the POSNOC website: http://www.posnoc.co.uk
The study is being led by Associate Professor Amit Goyal from the Royal Derby Hospital and is being coordinated by the Nottingham Clinical Trials Unit at the University of Nottingham and Sussex Health Outcomes Research & Education in Cancer at the University of Sussex. The study is funded by the National Institute for Health Research’s Health Technology Assessment Programme.
— Ends —
Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email email@example.com or see the Globelynx website for how to register for this service.
For up to the minute media alerts, follow us on Twitter
Notes to editors:
The University of Nottingham is a research-intensive university with a proud heritage, consistently ranked among the world's top 100. Studying at the University of Nottingham is a life-changing experience and we pride ourselves on unlocking the potential of our 44,000 students - Nottingham was named University of the Year for Graduate Employment in the 2017 Times and Sunday Times Good University Guide, was awarded gold in the TEF 2017 and features in the top 20 of all three major UK rankings. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement. We are ranked eighth for research power in the UK according to REF 2014. We have six beacons of research excellence helping to transform lives and change the world; we are also a major employer and industry partner - locally and globally.
Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…